ROCHESTER, N.Y., Sept. 24, 2019 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and Huntington’s disease, today announced that Maurice Zauderer, PhD, President and Chief Executive Officer, will present a corporate overview and business update at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24th in New York City. Dr. Zauderer will review updated interim data of the Phase 1b/2 study of pepinemab, VX15 anti-semaphorin 4D antibody, in combination with anti-PD-L1 checkpoint inhibitor, BAVENCIO® (avelumab), in non-small cell lung cancer (NSCLC) as well as the continuing progress of Vaccinex’s ongoing, potentially pivotal study of pepinemab as a single agent to treat Huntington’s disease. Further details of the NSCLC study will be presented on Friday, September 27 at the Fifth International Cancer lmmunotherapy Conference to be held in Paris, France.
| Ladenburg Thalmann 2019 Healthcare Conference | |
| Date: | Tuesday, September 24 |
| Time: | 1:30pm Eastern Time |
The updated corporate presentation can be downloaded on the Presentations page of the Company’s website at www.vaccinex.com.
About Vaccinex, Inc.
Vaccinex, Inc. is a clinical-stage immunotherapy company engaged in the discovery and development of targeted biotherapeutics to treat serious diseases and conditions with unmet medical needs, including cancer, neurodegenerative diseases, and autoimmune disorders, with currently active clinical trials in Non-Small Cell Lung Cancer and Huntington’s disease. Vaccinex is based in Rochester, New York.
To receive Vaccinex news as it happens, please sign up for News Alerts on the Company’s Investor Services web page (Investors/Investor Services).
Investor Contact
Jeremy Feffer
LifeSci Advisors, LLC
212-915-2568
jeremy@lifesciadvisors.com
Forward Looking Statement
To the extent that statements contained in this press release are not descriptions of historical facts regarding Vaccinex, Inc. (“Vaccinex,” “we,” “us,” or “our”), they are forward-looking statements reflecting management’s current beliefs and expectations. Such statements include, but are not limited to, statements about our plans, expectations and objectives with respect to clinical trials, and other statements identified by words such as “may,” “will,” “appears,” “expect,” “anticipate,” “estimate,” “intend,” “hypothesis,” “potential,” “advance,” and similar expressions or their negatives (as well as other words and expressions referencing future events, conditions, or circumstances). Forward-looking statements involve substantial risks and uncertainties that could cause our research and pre-clinical development programs, clinical development programs, future results, performance, or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, uncertainties inherent in the execution, cost and completion of preclinical and clinical trials, uncertainties related to regulatory approval, risks related to our dependence on our lead product candidate pepinemab (VX15/2503), and other matters that could affect our development plans or the commercial potential of our product candidates. Except as required by law, we assume no obligation to update these forward-looking statements. For a further discussion of these and other factors that could cause future results to differ materially from any forward-looking statement, see the section titled “Risk Factors” in our periodic reports filed with the Securities and Exchange Commission (“SEC”) and the other risks and uncertainties described in our Form 10-K dated March 13, 2019 and subsequent filings with the SEC.